Doctors have hailed “unprecedented” trial results that show a triple-action cancer jab can eradicate entire tumours in patients.

In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.

The jab, called #amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks.
In 15 of them, doctors found the drug had melted away their tumours altogether.

Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said:
“These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy.
“This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking.”
Harrington, also a consultant oncologist at the Royal Marsden NHS foundation trust, added:

“This treatment has the potential to benefit many thousands of patients each year.”

Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip,
making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.

Most side-effects of the treatment, given once every three weeks,
were mild to moderate,
with fewer than one in 10 patients forced to stop their treatment
https://www.theguardian.com/science/2026/may/30/cancer-jab-can-eradicate-entire-tumours-in-patients-trial-shows?CMP=Share_iOSApp_Other

Cancer jab can eradicate entire tumours in patients, trial shows

"The jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether."

#cancerresearch #cancertreatment #amivantamab

https://www.theguardian.com/science/2026/may/30/cancer-jab-can-eradicate-entire-tumours-in-patients-trial-shows?CMP=Share_AndroidApp_Other

Trial shows smart injection drug shrinks head and neck cancer tumors in six weeks

Researchers have presented promising results from a clinical trial demonstrating that amivantamab, a triple-action drug delivered via injection, can significantly shrink tumors in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) within six weeks. This form of cance... [More info]